Promosyon programı Inventiva S.A.
Gelişmiş program
Basit grafik
Şirket hakkında Inventiva S.A.
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of mucopolysaccharidoses type VI disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.| IPO date | 2020-07-10 |
|---|---|
| ISIN | US46124U1079 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Сайт | https://www.inventivapharma.com |
| Цена ао | 3 |
| Günlük fiyat değişimi: | -0.6667% (3) |
|---|---|
| Haftalık fiyat değişimi: | -4.18% (3.11) |
| Aylık fiyat değişimi: | +24.17% (2.4) |
| 3 ayda fiyat değişimi: | +21.63% (2.45) |
| Altı ayda fiyat değişimi: | +34.84% (2.21) |
| Yıllık fiyat değişimi: | -25.69% (4.01) |
| 3 yılda fiyat değişimi: | -73.46% (11.23) |
| 5 yılda fiyat değişimi: | 0% (2.98) |
| 10 yılda fiyat değişimi: | 0% (2.98) |
| Yılbaşından bu yana fiyat değişimi: | +35.45% (2.2) |
|
|
Hafife alma
|
Yeterlik
|
|||||||||||||||||||||||||||||||||||||
Temettüler
|
Görev
|
Büyüme dürtüsü
|
|||||||||||||||||||||||||||||||||||||
| Kurumlar | Hacim | Paylaşmak, % |
|---|---|---|
| Yiheng Capital Management, L.P. | 2644926 | 5.08 |
| NEA Management Company, LLC | 1462586 | 2.81 |
| BVF Inc. | 686040 | 1.32 |
| Commonwealth Equity Services, LLC | 36265 | 0.07 |
| TWO SIGMA SECURITIES, LLC | 13005 | 0.02 |
| Ewa, LLC | 11898 | 0.02 |
| Morgan Stanley | 5900 | 0.01 |
| UBS Group AG | 254 | 0 |
| Süpervizör | İş unvanı | Ödeme | Doğum yılı |
|---|---|---|---|
| Mr. Frederic Cren | Co-Founder, CEO & Chairman | 521.29k | 1966 (59 yıllar) |
| Dr. Pierre Broqua Ph.D. | Co-Founder, Chief Scientific Officer, Deputy CEO & Director | 450.22k | 1962 (63 yıl) |
| Mr. Jean Volatier | Deputy GM & CFO | N/A | 1964 (61 yıl) |
| Mr. Eric Duranson L.L.M. | General Counsel | N/A | 1974 (51 yıl) |
| Ms. Nathalie Harroy | Head of Human Resources | N/A | 1967 (58 yıllar) |
| Dr. Michael Cooreman | Chief Medical Officer | N/A | 1958 (67 yıllar) |
| Ms. Alice Roudot-Ketelers Pharm.D. | Chief Operating Officer | N/A | 1971 (54 yıl) |
| Ms. Pascaline Clerc Ph.D. | Executive Vice President of Strategy & Corporate Affairs | N/A | 1980 (45 yıllar) |
| Dr. Kristina Meyer Ph.D. | Executive VP and Business Development & Alliance Management |
Adres: France, Daix, 50 rue de Dijon - Google haritalarda aç, Yandex haritalarını aç
Web sitesi: https://www.inventivapharma.com
Web sitesi: https://www.inventivapharma.com
